Related Announcements

PAR-21-065 - Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to correct a reference to the companion Funding Opportunity Announcement (FOA), as well as the Application Types Allowed in Section II of PAR-21-065, "Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)".

First, the following reference to the companion FOA has been corrected:

Currently Reads:

Section I. Funding Opportunity Description

• This R25 FOA provides support for curriculum or methods development projects that may require up to 2 years to develop, test, and prepare for dissemination, prior to being offered to the intended participant audience. It does not support the actual offering of the developed curriculum or methods to identifiable participants at the applicant institution or elsewhere, which may be able to be supported through the companion funding opportunity, PAR-21-066, Cancer Research Education Grants Program - Courses for Skills Development (R25).

Modified to Read (change shown in bold italics):

Section I. Funding Opportunity Description

• This R25 FOA provides support for curriculum or methods development projects that may require up to 2 years to develop, test, and prepare for dissemination, prior to being offered to the intended participant audience. It does not support the actual offering of the developed curriculum or methods to identifiable participants at the applicant institution or elsewhere, which may be able to be supported through the companion funding opportunity, PAR-21-278, Cancer Research Education Grants Program - Courses for Skills Development (R25).

Secondly, the following section of PAR-21-065 has been corrected to reflect that "Renewal" applications are not allowed:

Currently Reads:

Section II. Award Information

Application Types Allowed

New

Resubmission

Renewal

Modified to Read:

Section II. Award Information

Application Types Allowed

New

Resubmission

All other aspects of PAR-21-065 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Sergey Radaev, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5630
Email: [email protected]

Peer Review Contact(s)

Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: [email protected]

Financial/Grants Management Contact(s)

Amy Bartosch
National Cancer Institute (NCI)
Telephone: 240-276-6912
Email: [email protected]